Infectious Disease Control
China recalibrates its COVID-19 response strategy
BEIJING, Dec. 12, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn onDecember 7 that they would no longer be required to take the ...
2022-12-12 10:22
1955
Asia embraces the dawn
HONG KONG, Dec. 10, 2022 /PRNewswire/ -- A photo exhibition that captures the changes in Asian people's daily lives under the COVID-19 pandemic and encourages people to move forward opened inHong Kong on Friday. Co-organized by China Daily and the Asia News Network, the Changing Asia – New Norma...
2022-12-10 00:31
9329
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...
2022-12-05 20:00
1545
Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...
2022-11-28 22:59
4033
Australian Scientists Honoured with the Grand Hamdan Award
DUBAI, UAE, Nov. 25, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future. The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of SheikhRas...
2022-11-25 10:39
3209
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...
2022-11-23 19:43
3780
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) a...
2022-11-21 20:00
1864
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease ar...
2022-11-21 18:56
3826
Manulife Hong Kong expands partnership with Christian Family Service Centre to support long COVID recovery in underserved communities
New program to provide comprehensive healthcare services to empower sustained health and better wellbeing HONG KONG, Nov. 17, 2022 /PRNewswire/ -- Manulife Hong Kong today announced the launch of "Manulife Health Voucher Program – COVID Recovery" (hereafter referred to as the "Program") in partn...
2022-11-17 14:22
2572
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021
VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...
2022-11-16 21:00
4268
Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022
XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipmen...
2022-11-15 21:19
2798
WuXi Vaccines Establishes New Vaccines CDMO Facility in China
SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Va...
2022-11-15 12:45
1802
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
* The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary * Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains * The trial showed no benefit for a bivalent vaccin...
2022-11-08 21:00
3403
Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria
SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...
2022-11-08 20:25
1677
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...
2022-11-07 21:00
1979
2nd Global Forum of People's Organizations on Hansen's Disease Focuses on Capacity Building to Promote Dignity of Those Affected by the Disease
TOKYO, Nov. 3, 2022 /PRNewswire/ -- The 2nd Global Forum of People's Organizations on Hansen's Disease takes place inHyderabad, India, from November 6 to 8, 2022. Organized by Sasakawa Leprosy (Hansen's Disease) Initiative as part of its "Don't Forget Leprosy" campaign, the forum is being held a...
2022-11-03 21:00
1819
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...
2022-11-02 08:10
2419
GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis
SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supportedChulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production a...
2022-11-01 11:39
3604
Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022
SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened onOctober 20, 2022. As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo. As an international and frontier city of ...
2022-10-26 16:52
2029
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
* CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available for late-stage development. * SK bioscience to secure new vaccines and establish pandemic response system * SK bioscience to enhance human healt...
2022-10-25 20:00
2262
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5902
